ISDA: 5TQ4

Deposition Date 2016-10-23

Release Date 2017-01-11

Last Version Date 2024-11-20

Entry Detail

PDB ID:

5TQ4

Keywords:

Transferase/Transferase Inhibitor

Title:

Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Homo sapiens

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.30 Å

R-Value Free:

0.27

R-Value Work:

0.24

R-Value Observed:

0.24

Space Group:

C 2 2 21

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Tyrosine-protein kinase JAK2
Gene (Uniprot):JAK2
Mutagens:M1073S, F1076T
Chain IDs:A
Chain Length:298
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:O60674 Pfam ID:PF07714 EC:2.7.10.2

Modified Residue

Compound ID	Chain ID	Parent Comp ID	Details	2D Image
PTR	A	TYR	modified residue

Ligand Molecules

7GY

Primary Citation

Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin.

Jones, P, Storer, R.I, Sabnis, Y.A, Wakenhut, F.M, Whitlock, G.A, England, K.S, Mukaiyama, T, Dehnhardt, C.M, Coe, J.W, Kortum, S.W, Chrencik, J.E, Brown, D.G, Jones, R.M, Murphy, J.R, Yeoh, T, Morgan, P, Kilty, I.Show

J. Med. Chem. 60 767 786 (2017)

PMID: 27983835 DOI: 10.1021/acs.jmedchem.6b01634

Abstact

By use of a structure-based computational method for identification of structurally novel Janus kinase (JAK) inhibitors predicted to bind beyond the ATP binding site, a potent series of indazoles was identified as selective pan-JAK inhibitors with a type 1.5 binding mode. Optimization of the series for potency and increased duration of action commensurate with inhaled or topical delivery resulted in potent pan-JAK inhibitor 2 (PF-06263276), which was advanced into clinical studies.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form